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Background: Human immunodeficiency virus (HIV) gene expression is primarily regulated at the step of
transcription elongation. The viral Tat protein recruits the Positive Transcription Elongation Factor b (P-TEFb) and
the Super Elongation Complex (SEC) to the HIV promoter and enhances transcription by host RNA polymerase II.
Results: To map residues in the cyclin box of cyclin T1 that mediate the binding of P-TEFb to its interacting host
partners and support HIV transcription, a pool of N-terminal cyclin T1 mutants was generated. Binding and functional
assays in cells identified specific positions in cyclin T1 that are important for (i) association of P-TEFb with Hexim1,
Cdk9 and SEC/AFF4 (ii) supporting Tat-transactivation in murine cells and (iii) inhibition of basal and Tat-dependent
HIV transcription in human cells. Significantly, a unique cyclin T1 mutant where a Valine residue at position 107 was
mutated to Glutamate (CycT1-V107E) was identified. CycT1-V107E did not bind to Hexim1 or Cdk9, and also could not
assemble on HIV TAR or 7SK-snRNA. However, it bound strongly to AFF4 and its association with HIV Tat was slightly
impaired. CycT1-V107E efficiently inhibited HIV replication in human T cell lines and in CD4(+) primary cells, and
enforced HIV transcription repression in T cell lines that harbor a transcriptionally silenced integrated provirus.
Conclusions: This study outlines the mechanism by which CycT1-V107E mutant inhibits HIV transcription and enforces
viral latency. It defines the importance of N-terminal residues of cyclin T1 in mediating contacts of P-TEFb with its
transcription partners, and signifies the requirement of a functional P-TEFb and SEC in mediating HIV transcription.
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Since its discovery, Human Immunodeficiency Virus type
1 (HIV-1), the causative agent of AIDS, has led to the
death of close to 25 million people worldwide. Despite the
availability of effective anti-HIV therapy (HAART) that
successfully limits HIV replication, HAART has failed
to completely eradicate HIV. Cell-cell spread permits
ongoing viral replication and drug-resistant variants
appear. Moreover, once therapy is interrupted, tran-
scriptional silent proviruses re-emerge from infected
cell reservoirs and viral replication resumes [1-4].
HIV has become a model for studying transcriptional
elongation in eukaryotes, where the viral protein Tat* Correspondence: rantaube@bgu.ac.il
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unless otherwise stated.serves as a master regulator of viral transcription. It
directly binds to the host cyclin T1 (CycT1) and assem-
bles on the transactivation response RNA element-TAR.
Tat thus recruits the Positive Transcription Elongation
Factor b (P-TEFb) to the viral promoter and stimulates
HIV gene transcription. The Cdk9 kinase subunit of
P-TEFb then phosphorylates the C-terminal domain
(CTD) of RNA Polymerase II (RNAPII), as well as
negative factors, Spt5 and NELF [5-8], to release RNAPII
from its pausing and promote viral transcription [7,9-11].
In cells, P-TEFb associates with a second transcription
complex - Super Elongation Complex (SEC) [12-14]. Both
complexes synergistically act on the same RNAPII and
enhance transcription. The ELL2 subunit of SEC increases
the catalytic activity of RNAPII by preventing its back-
tracking and pausing [15]. ELL2 expression is regulated by
the E3 ubiquitin ligase, Siah1, which targets the protein
for degradation. In infected cells, Tat also associates withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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P-TEFb-SEC complex formation [12-14,16]. In SEC, AF4/
FMR2 family member 4 (AFF4) acts as a scaffold that
bridges P-TEFb to SEC [14]. Structural and biochemical
studies have shown that AFF4 recognizes P-TEFb through
a weak direct interaction with the N-terminus 300 region
of CycT1. This interaction is slightly increased when
Cdk9 is coupled to CycT1. AFF4 also establishes direct
contacts with Tat, which significantly increases the
affinity of P-TEFb to SEC. Recently, AFF1 has also been
reported to be part of P-TEFb complex [17]. AFF1
increases the affinity of Tat to CycT1 and enhances the
release of P-TEFb from its inactive 7SK-snRNP complex
to stimulate Tat transactivation and HIV replication.
Structural analysis of AFF4/SEC shows it possesses a
Tat-binding pocket at the first 300-N-terminal region.
Upon AFF4 binding to P-TEFb, Cdk9 undergoes struc-
tural changes though is not considered a primary partner
of AFF4 [18].
As P-TEFb is essential for HIV replication, its activity is
tightly regulated in cells. In vivo, there exists equilibrium
between active and non-active P-TEFb. The active com-
plex consists of Cdk9 and either cyclin T1, T2a or T2b,
while the non-active complex comprises of Cdk9, cyclin
T1, and the 7SK snRNP. The latter comprises of a 7SK
small nuclear non-coding RNA (snRNA) and the HMBA-
inducible protein 1 or 2 (Hexim1/2) [19,20]. In vivo,
7SK snRNA forms a core complex with the MePCE and
LARP7 proteins [21]. C-terminal residues of Hexim1
mediate binding to CycT1, while C-terminal residues of
the cyclin box of CycT1 are important to the interac-
tions with Hexim1 [22-26]. Importantly, Tat and Hexim1
compete for CycT1, as the same Tat-TAR recognition
motif (TRM) on CycT1 also binds Hexim1 [26,27]. Never-
theless, we have recently demonstrated that separate bind-
ing surfaces on the N-terminal residues of CycT1 are
involved in association with Tat or Hexim1 [28].
The structure of P-TEFb, Hexim1 and 7SK RNA have
been solved by X-ray crystallography or NMR spectros-
copy [18,29-35]. However, little is known on the binding
surfaces of P-TEFb/CycT1 that mediate the complex
interactions with its transcription partners, mainly AFF4,
Hexim1 and Cdk9 and their involvement in mediating
HIV transcription. Moreover, the significant of either P-
TEFb or SEC to transcription is also not fully understood.
Herein, an extensive biochemical analysis was performed
on a pool of N-terminal CycT1 mutants that were gener-
ated by error prone PCR on the cyclin box of CycT1.
CycT1 mutants were analyzed for binding to Hexim1,
Cdk9, AFF4 and Tat. The ability of CycT1 mutants to
support Tat transactivation in murine and human cells
was monitored. A unique V107E mutant of CycT1 was
identified. HA-CycT1-V107E did not bind Hexim1, or
Cdk9 and its association with Tat was slightly diminished.However, CycT1-V107E strongly bound to AFF4. It also
did not assemble onto P-TEFb RNA targets - TAR RNA
and 7SK snRNA. Importantly, HA-CycT1-V107E efficiently
inhibited HIV replication in human T cell lines and in
CD4(+) primary cells. This mutant also inhibited Tat-
independent basal transcription and rapidly enforced
transcriptional repression of HIV. Overall, this study
defines a role for the cyclin box N-terminal residues of
CycT1 in mediating contacts of P-TEFb with its interact-
ing partners Cdk9, Hexim1 and AFF4. It also provides a
mechanistic explanation for the inhibitory function of a
unique CycT1-V107E on HIV gene transcription and
signifies the importance of a functional P-TEFb and
SEC unit in mediating HIV transcription.
Results
Association of HA-Cyclin T1 mutants with Cdk9 and
Hexim1 in cells
To identify residues in the cyclin box of cyclin T1 (CycT1)
that are involved in association of CycT1 with Cdk9,
Hexim1 or AFF4 of SEC transcription partners, as well as
support HIV transcription, an error prone PCR-based
mutagenesis was used to generate a pool of N-terminal
human CycT1 mutants as described by Verstraete et.al.
(submitted; Table 1). HA-tagged-CycT1 mutants were
generated in the context of [1–280] residues, sub-cloned
into a lentivector, and were transiently expressed in
human HEK-293T cells. Western Blot (WB) analysis
confirmed expression of HA-CycT1 mutants (Figure 1).
Immuno-Precipitation (IP) experiments were then per-
formed in cells to examine the association of HA-CycT1
mutants with host Cdk9, Hexim1 and SEC/AFF4. Binding
efficiencies were compared to those of HA-CycT1-wild
type (Table 1). Based on their abilities to associate with
Cdk9 and Hexim1, HA-CycT1 mutants were divided into
four groups (Table 1). Group I, consisted of HA-CycT1
mutants that bound to Cdk9 and Hexim1, as efficiently as
wild-type Ha-CycT1. Group II mutants, exhibited weak
binding to both Hexim1 and Cdk9. These include Q56R;
R68I; P85L; Q97K; V104G; C111R; K168E; D169P, P249L
HA-CycT1 mutants. Group III, consisted of HA-CycT1
mutants that did not bind to Hexim1, yet they bound to
Cdk9. In some cases this interaction was weaker than that
detected for HA-CycT1-wild type. This group included
N60K, L133R, Y175E and Y175S. Importantly, these
HA-CycT1 mutants were the first single-point mutations
that have been reported to bind to Cdk9 but not to
Hexim1. A last and interesting group, Group IV of HA-
CycT1 mutants, lost their ability to associate with both
Cdk9 and Hexim1. This group included HA-CycT1-U7
[28], V107E; L203P; and the quadruple mutant-[T143A;
149A;155A;E137D]. All HA-CycT1 mutants in this group
were impaired in their binding to AFF4/SEC, except HA-
CycT1-V107E (Table 1). Overall, most N-terminal helices
Table 1 Summary of HA-Cyclin T1 point mutations




Inhibition of Tat activity
[human cells3]
Group I
wild type +++ +++ +++ 100 100 -
H239A +++ +++ +++ 64 110 -
T143;149A;155A +++ +++ +++ 33 108 -
T143A;155A +++ +++ +++ 65 107 -
Q46A +++ +++ +++ 73 103 -
Q50A +++ +++ +++ 79 111 -
159 F +++ +++ +++ 17 97 -
F176A +++ +++ +++ 25 54 -
Q46A;50A;F176A +++ +++ +++ 20 81 -
R38S +++ +++ +++ 41 69 -
M71E +++ +++ +++ 72 100 -
H154R +++ +++ +++ 32 123 -
L170W +++ +++ +++ 11 95 -
T179A +++ +++ + 41 74 -
W221R +++ +++ + 17 101 -
F241S +++ +++ +++ 37 115 -
Group II
Q56R + + + 7 104 -
R68I + + - 39 105 -
P85L + + +++ 34 76 -
Q97K + + +++ 42 85 -
V104G + + + 80 160 -
C111R +++ + +++ 16 90 -
K168E + + +++ 58 125 -
D169P + + +++ 66 89 -
P249L + + +++ 9 109 -
Group III
N60K - + - 50 114 +
L133R - + +++ 69 70 -
Y175S - +++ +++ 22 107 -















Table 1 Summary of HA-Cyclin T1 point mutations (Continued)
Group IV
V107E - - +++ 12 28 +
L203P - - - 17 102 -
U7 - - - 4 141 +
T143A;149A;155A;E137D - - - 15 92 -
HA-Cyclin T1 mutations were generated by random mutagenesis as described (Verstraete et.al.). Protein interactions between HA-CycT1 mutants and P-TEFb transcription partners (Hexim1; Cdk9; AFF4) were monitored
in human HEK-293T cells, following over expression of the HA-CycT1 mutants. Cells were transfected with HA-CycT1 mutants and 48 hr. later were lysed and subjected to Immuno-Precipitation (IP) with α-HA antibody.
Precipitated HA-CycT1 proteins were then analyzed by SDS-PAGE and WB for association with endogenous partners of P-TEFb - Hexim1; Cdk9 and AFF4. Binding efficiencies are presented as (+++) for efficient binding,
which is comparable to HA-CycT1-wild type, (+) for weak binding, or (−) for lack of protein interactions respectively.
(1) Rescue of HIV Tat transactivation in murine cells - Table 1 also summarizes the ability of HA-CycT1 mutants to activate Tat-dependent transcription from the HIV-LTR promoter in murine cells and corresponds to Data in
Figure 1. Experiments were performed in 3T3 cells that were co-transfected with the HIV-LTR promoter, which drives a luciferase reporter gene, HIV Tat and HA-CycT1. Luciferase readings were normalized to Renila expression.
Readings are presented relative to those obtained in cells that expressed HA-CycT1-wild-type - set to 100 (CycT1-wild type was set relatively to HIV-LTR-luciferase and Tat alone). Data is a representative of the mean value of
triplicate wells; error bars show± SEM.
Ability of HA-CycT1 mutants to inhibit Tat dependent HIV transcription in human cells was also tested as presented in Figure 2.
(2) Inhibition of Tat-independent HIV transcription in human cells by HA-CycT1 mutants - cells were co-transfected with HIV-LTR-luciferase reporter gene and HA-CycT1 mutant 48 hr. post transfection cells were harvested and
their luciferase activities were measured. Luciferase readings were normalized to Renila expression and are presented relative to the readings obtained in cells that expressed HA-CycT1-wild-type alone - set to 100. Results are
representative of the mean value of triplicate wells; error bars show ± SEM.
(3) Inhibition of Tat-dependent HIV transcription in human cells by HA-CycT1 mutants - HEK-293T cells were transfected with two concentrations of HA-CycT1 mutants and the LTR-Tat-BFP reporter provirus 48 hr. post transfection, cells
were harvested and the percentage of cells that expressed BFP was measured by FACS. Cells were also introduced with a pCDNA-CMV-GFP expression plasmid to control for transfection efficiencies by measuring percentage of GFP















Figure 1 Analysis of HIV Tat transactivation in murine cells upon expression of HA-CycT1 mutants. 3T3 murine cells were co-transfected
with the HIV-LTR-Luciferase reporter gene, HIV Tat and each of the HA-CycT1 mutants expressing plasmids. 48 hr. post transfection cells were
harvested and their Tat-dependent luciferase activities were measured. Luciferase readings were normalized to Renila expression and data are
presented relative to the readings obtained in cells that expressed human HA-CycT1-wild-type – set to 100 (assays were measured relative to cells
that expressed HIV LTR-Luc reporter and Tat alone). HA-CycT1 mutants are divided to four groups according to their binding to Cdk9 and Hexim1
(Table 1). Asterisks mark specific HA-CycT1 mutants that were severely impaired in their ability to rescue Tat transactivation. Results are representative
of the mean value of triplicate wells; error bars show± SEM.
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impaired in their AFF4 binding, also did not bind Cdk9
or Hexim1 (or bound very weak to both), and as such
were part of groups II-IV (N60K; R68I; L203P U7,
[T143A;149A;155A;E137D]) [28].
Ability of HA-CycT1 mutants to support Tat transactivation
in murine cells
To screen HA-CycT1 mutants for their ability to support
Tat transactivation, experiments were performed in mur-
ine 3T3 cells (Figure 1). Murine CycT1 binds weakly to
HIV Tat, thus cannot enhance Tat transcriptional activity.
Ectopic expression of human CycT1 in these cells rescues
Tat activity and stimulates HIV transcription [8]. HA-
CycT1 mutants were transiently expressed in murine
cells in the presence of the HIV-LTR-Luciferase (Luc)
and HIV Tat. The ability of each of the HA-CycT1 mutants
to enhance Tat transactivation was compared to that
of wild type HA-CycT1 - set to 100. Expression of HA-
CycT1 mutants was confirmed by anti-HA western blot
in 3T3 cells. All HA-CycT1 mutants were impaired, to
some extent, for their ability to support Tat activity in
murine cells (Table 1). HA-CycT1 mutants that did not
bind to Cdk9 or Hexim1 (Group IV) exhibited the
weakest Tat transactivation levels. HA-CycT1-V107E;L203P, the quadruple mutant T143A;149A;155A;E137D
and HA-CycT1-U7 mutant were the least efficient [28].
HA-CycT1 mutants from Group III, which did not bind
Hexim1, yet bound to Cdk9, also showed decreased
ability to support Tat transactivation in murine cells.
HA-CycT1 mutants Y175E and Y175S were particularly
worth noticing. HA-CycT1 mutants that bound weakly
to both Hexim1 and Cdk9 (Group II), all exhibited
lower levels of supporting Tat function compared to
HA-CycT1-wild type. However, levels of Tat transacti-
vation were variable and relatively high when com-
pared to mutants of group IV. While HA-CycT1-V104G;
D169P; K168E mutants supported Tat function to levels
of above 50% relatively to human HA-CycT1-wild-type,
Q56R, R68I, P85L, Q97K, C111R, and P249L HA-CycT1
mutants exhibited low efficiencies of Tat transactiva-
tion in 3T3 cells (Table 1; Figure 1). Q56R, C111R and
P249L HA-CycT1 mutants were severely impaired in
their ability to activate Tat function. Finally, HA-CycT1
mutants that bound to Hexim1 and Cdk9 at levels
similar to those of the wild type HA-CycT1 (Group I)
also exhibited variable levels of Tat transactivation in
murine cells. Interestingly, HA-CycT1 mutants I59F,
F176A, L170W, W221R, and the triple mutant Q46A;
Q50A;F176A exhibited low levels of Tat transactivation in
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CycT1 lead to decreased capacity to support Tat-dependent
activation of HIV LTR in murine cells (Figure 1).Ability of HA-CycT1 mutants to support Tat-independent
and Tat-dependent transcription in human cells
We further analyzed the ability of HA-CycT1 mutants to
mediate Tat-independent basal transcription from the
HIV LTR in human HEK293T cells. These experiments
were performed by transiently transfecting each of the
HA-CycT1 mutants and the HIV-LTR- luciferase reporter,
in the absence of HIV Tat. Effects of HA-CycT1 mutants
on basal transcription were determined relatively to
ability of wild type HA-CycT1 to activate transcription
activity from the HIV LTR promoter – set to 100
(Table 1). Generally, without Tat, CycT1-wild type weakly
activated the HIV promoter – up to only about 2 fold.
Most HA-CycT1 mutants presented comparable levels of
stimulation of basal transcription from the LTR to those
detected for wild type HA-CycT1 (Table 1). Some HA-
CycT1 mutants - T179A, L133R and Y175E exhibited
slightly lower levels of HIV LTR-activation - around 70%
relative to cells that expressed HA-CycT1-wild type. Other
HA-CycT1 mutants - H154R, K168E, and U7 showed
slightly higher basal transcription activation of the HIV
LTR relative to the HA-CycT1-wild type. These results
however are in the range of assay error and should not
be distinguished from the wild type activity levels.
Nevertheless, one mutant, HA-CycT1-V107E that did
not bind to Hexim1 or Cdk9 stood out among all
others and could not activate basal transcription of the
HIV promoter. Its activation reached only to 28% rela-
tive to HA-CycT1-wild type. This mutant was further
analyzed in more details - see below.
HA-CycT1 mutants were next analyzed in human cells
for inhibition effects on Tat-dependent transcription from
the viral LTR promoter (Table 1). HA-CycT1 mutants
were transiently expressed in HEK-293T cells together
with HIV-LTR-Tat-BFP (Blue Florescence Protein) reporter
provirus. Cells were then analyzed by FACS for their ability
to inhibit HIV-LTR-mediated BFP expression. Most of
the HA-CycT1 mutants did not affect HIV transcrip-
tion in human cells (Table 1). However, there were two
notable exceptions that displayed strong inhibitory
effects on Tat-dependent transactivation in human cells.
HA-CycT1-U7 (which consists of four point mutation
and a deletion [28]) and HA-CycT1-V107E (Figure 2a).
Both mutants were impaired for their binding to Hexim1
and Cdk9. However, only HA-CycT1-V107E bound
AFF4/SEC, while HA-CycT1-U7 did not (Table 1). Inter-
estingly as noted above, HA-CycT1-V107E also displayed
inhibitory effects on Tat-independent transactivation of
the HIV LTR in the absence of Tat. Further analysis
also verified that inhibition of basal transcription fromHIV LTR by HA-CycT1-V107E was specific, as tran-
scription from a CMV-BFP promoter was not inhibited
by either HA-CycT1-wild type, or HA-CycT1-V107E
(Figure 2b).
Association of CycT1-V107E with P-TEFb partners and its
RNA targets
Protein or RNA binding experiments in cells demonstrated
that HA-CycT1-wild type bound efficiently to TAR RNA
and to 7SK-snRNA (Figure 3a + b), as well as to Hexim1,
AFF4, Brd4, Cdk9 and Tat (Figure 3d). In contrast, HA-
CycT1-V107E neither associated with Hexim1 nor Cdk9
and Brd4 (Figure 3d), not with TAR and 7SK snRNA
(Figure 3a + b). Its binding to Tat was slightly diminished,
and it exhibited strong binding to AFF4/SEC. These results
were in agreement with the Hexim1-binding deficiency
of HA-CycT1-V107E (Figure 3d). To better characterize
the mechanism of CycT1-V107E-mediated inhibition of
HIV transcription, stable expression of HA-CycT1-wild
type, or V107E was obtained in HEK-293T by lentiviral
transduction and drug selection. The incorporation of
Cdk9 onto the Tat-CycT1 complex was monitored in
these cells, upon expression of Flag-Tat. Cells were
subjected to anti-Flag IP, and the efficiency of Cdk9
associated with Tat and HA-CycT1-wild type was ana-
lyzed. As shown, expression of HA-CycT1-V107E and
Tat, led to lower expression levels of Cdk9 in the com-
plex, compared to cells that expressed HA-CycT1-wt.
These results imply that the CycT1-V107E squelches
Tat from the P-TEFb (Figure 3c).
HA-CycT1-V107E mutant inhibits HIV replication in T cells
and in primary CD4(+) T cells
Inhibitory effects of HA-CycT1-V107E on HIV tran-
scription were further investigated in human T cell lines
(Figure 4). For this purpose, Jurkat (J)-LTR-Tat-BFP T cells,
which harbor a transcriptionally silenced HIV-LTR-Tat-BFP
integrated provirus, were utilized, similarly to J-LTR-Tat-
d2EGP cells that were previously descried by the Karn lab
[36]. The basal LTR expression in these cells was relatively
low - close to 10% and thus, cells were suitable for studying
viral latency. Jurkat (J)-LTR-Tat-BFP T cells that stably
expressed either wild type or V107E HA-CycT1 were
generated by lentiviral transduction (J-LTR-Tat-BFP/
HA-CycT1-V107E, or J-LTR-Tat-BFP/HA-CycT1-wild type).
48 hr. post transduction, cells were subjected to selec-
tion with puromycin for additional 3-10 days to obtain
HA-CycT1 stable cells. HA-CycT1 expression was validated
by western blotting (Figure 4a-lower panel). Stable cells
expressing HA-CycT1 (wild type or V107E) were then
analyzed by FACS for their HIV-Tat-LTR-BFP expression.
While close to 100% of LTR-Tat-BFP/HA-CycT1-wild-
type cells expressed BFP, only 20% of J-LTR-Tat/HA-
CycT1-V107E cells expressed BFP. We conclude that
Figure 2 HA-CycT1-V107E mutant inhibits HIV transcription in human cells. a) HA-CycT1-V107E inhibits HIV-Tat dependent transcription from the
HIV LTR promoter - HEK-293T cells were transfected with increasing concentrations of the HA-CycT1-V107E mutant and the LTR-Tat-BFP provirus lentivector
using Lipofectamin 2000. 48 hr. post transfection cells were harvested and the percentage of cells that expressed BFP was measured by FACS. Data are
presented relative to cells that did not express HA-CycT1-V107E - set to 100. Lower panel shows Western blot that confirmed HA-CycT1-V107E expression
and equal expression levels of actin. b) HA-CycT1-V107E does not inhibit basal transcription from the CMV promoter - HEK-293T were co-transfected with
HA-CycT1-wild type or HA-CycT1-V107E mutant in the presence of the CMV-BFP reporter promoter. 72 hr. post transfection, cells were harvested and their
BFP expression was monitored by FACS. The percentage of BFP expressing cells in the presence of HA-CycT1 wild type was set to 100. Results are the
average of there independent experiments. Error bars show± SEM values.
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transcription in J-LTR-Tat-BFP cells, while HA-CycT1-
wild-type activates HIV transcription in these cells
(Figure 4a; compare histogram for LTR-Tat-BFP/HA-
CycT1 wild type - light grey; versus J-LTR-Tat-BFP/HA-
CycT1-V107E -dark grey).
The ability of HA-CycT1-V107E to inhibit HIV repli-
cation was further validated in human CD4+ primary T
cells (Figure 4b). CD4(+) T cells were isolated and stimu-
lated for 3 days with CD3/CD28 T cell expanders beads,
supplemented with IL-2. Following activation, cells were
transduced with lentiviruses expressing either HA-CycT1-
V107E, or HA-CycT1-wild type and cells were propagated
for additional 3 days. The expression of HA-CycT1-V107E,
or HA-CycT1-wild type in CD4(+) primary cells was vali-
dated by western blotting, which confirmed efficient CycT1
gene marking (Figure 4b). Following, HA-CycT1 stable
CD4+ T cells were challenged with VSV-G pseudotyped
HIV-LTR-Tat-BFP lentivirus at MOI of one, and at 96 hr.
post infection HIV replication was analyzed by FACS. As
control, cells were transduced with a CMV-BFP lentivirus,
which is not dependent on Tat for full promoter activation
and generally displayed lower transcription activation.
As shown, expression of the HA-CycT1-V107E mutant
in CD4(+) primary cells led to a 60% inhibition of HIV
replication, relative to cells that expressed HA-CycT1-
wild type. Expression of either HA-CycT1 proteins did
not affect the transcription of the CMV-BFP lentivirus
(Figure 4b).HA-CycT1-V107E mutant enforces transcriptional
repression of HIV in T cell lines
The ability of HA-CycT1-V107E to enforce HIV transcrip-
tional repression was also tested following activation
of Jurkat cells with TNFα over longer periods of time
(Figure 5). Upon TNFα activation, 100% of J-LTR-Tat-
BFP stable cells (either HA-CycT1-wild type or HA-
V107E) were activated and expressed BFP, implying
that the HIV provirus in these cells was integrated, but
transcriptionally silent. Control J-Tat-BFP cells were also
activated with TNFα, and 100% of cells expressed BFP.
Following TNFα activation, cells were further grown for
additional 10–12 days and their LTR-Tat-BFP expression
was monitored by FACS at the indicated time points
post activation (Figure 5a). While cells that expressed
HA-CycT1-V107E quickly reverted back to basal LTR
transcription levels by day 12-post activation with
TNFα, J-LTR-Tat-BFP that expressed HA-CycT1-wild
type remained transcriptionally active and 100% of cells
expressed BFP. In fact most of J-LTR-Tat-BFP/HA-CycT1-
wild type cells died at day 12-post infection (Figure 5a).
TNFα activated control cells that did not express CycT1,
gradually lost their BFP expression in the 12 days time
frame, but still remained highly active. These results
demonstrate that HA-CycT1-V107E mutant efficiently
represses HIV transcription from the LTR and enforces
viral transcription silencing (Figure 5a).
To evaluate effects of HA-CycT1-V107E on HIV tran-
scription along longer periods of time points, J-LTR-Tat/
Figure 3 Association of HA-CycT1-V107E with P-TEFb interacting partners and its RNA targets. (a + b) HA-CycT1-V107E mutant does not
bind TAR or 7SK snRNA in cells – HEK-293T cells were co-transfected with HA-CycT1-V107E mutant, or HA-CycT1-wild type, HIV LTR-Luciferase and
pCDNA-Myc-Tat plasmids. 48 hr. post transfection, cells were lysed and immuno-precipitated (IP) with either anti-HA antibody, or control non-immune
anti-human IgG. RNA was extracted from IP and input samples (1%) and was then subjected to cDNA synthesis, which was further analyzed by real
time PCR using 7SK-snRNA (a) and TAR specific primers (b). Reactions were analyzed by real time PCR in triplicates and presented as fold of mean
enrichment relatively to PCR results obtained for cells transfected with LTR-Luciferase alone - set to 1. Error bars show ± SEM values. (c) Association of
HA-CycT1-V107E mutants with P-TEFb in cells – HEK-293T cells stably expressing either HA-CycT1-wild type or HA-V107E-CycT1 were co-transfected with
Flag-Tat using lipofectamin 2000 (Invitrogen). 48 hr. post transfection, cells were lysed and subjected to IP with α-Flag antibody. IP reactions
were analyzed by WB with a Cdk9 antibody. α-HA WB represents 1% of input of HA-CycT1. (d) Association of HA-CycT1-V107E mutants with
P-TEFb transcription partners in cells – HEK-293T cells stably expressing either HA-CycT1-wild type or HA-V107E-CycT1 were lysed and subjected
to IP with α-HA (left panel). IP reactions were analyzed by WB with the indicated antibodies.
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which led to activation of HIV transcription and reversion
to basal levels by day 12 post activation. J-LTR-Tat-BFP/
HA-CycT1-V107E stable cells were kept growing and at
day 35 post initial activation were activated again with
TNFα. HIV transcription was further monitored by FACS -
up to 60 days post-initial activation (Figure 5b). Following
the second TNFα activation at day 35, HA-CycT1-V107E
stable cells were activated but quickly reverted back to basal
HIV transcriptional levels and remained at these low levels
at 60 days post infection (Figure 5b).Discussion
In the current study a structural-biochemical analysis
was performed to determine the significant role of the
CycT1 cyclin box domain in mediating binding of P-
TEFb to its transcription partners - Hexim1, SEC/AFF4,
Cdk9 and HIV Tat. CycT1 mutants were generated via
random PCR, and their abilities to support Tat transacti-
vation in murine cells and to mediate Tat independent
(basal) and Tat dependent transcription from the HIV
LTR promoter in human cells were analyzed. This ana-
lysis led to the identification of a unique mutation - a
Figure 4 HA-CycT1-V107E mutant inhibits HIV transcription in T cells and primary CD4(+) cells. a) HA-CycT1-V107E inhibits HIV replication in
human T cell line - Jurkat T cells that harbor an integrated LTR-Tat-Rev-BFP provirus and express low levels of BFP (J-LTR-Tat-BFP), thus serve as model
for viral latency, were transduced with lentiviruses expressing either HA-CycT1-wild type or HA-CycT1-V107E. Transduced cells stably expressing human
CycT1 were generated following puromycin selection. J-LTR-Tat-BFP cells that did not express CycT1 were used as control. Cells were analyzed by FACS
for their LTR-BFP expression. Presented is a FACS spectra dot-blot analysis for J-LTR-Tat-BFP cells expressing HA-CycT1-V107E (J-LTR-Tat/HA-CycT1-V107E;
dark grey), or cells that expressed HA-CycT1-wild type (J-LTR-Tat/HA-CycT1 wild type; light grey spectra). The P3 gate was set based on J-LTR-Tat-BFP cells
that did not express CycT1. Data is a representative of three separate experiments. Bottom panel shows HA-CycT1 protein expression levels in Jurkat cells
as determined by anti-HA-WB. b) HA-CycT1-V107E inhibits HIV replication in primary CD4(+) T cells - Human CD4(+) T primary cells were isolated from naïve
PBMCs and stimulated with CD3/CD28 beads for 48 hr. Isolated cells were then transduced with either HA-CycT1-V107E or HA-CycT1-wild type expressing
lentivirus. 48 hr. post transduction, cells were infected with HIV-LTR-BFP, or CMV-BFP lentivirus at MOI of 1. BFP-mediated viral replication was analyzed by
FACS to monitor effects of HA-CycT1 expression. Expression of HA-CycT1-wild type or HA-CycT1-V107E was confirmed by anti-HA WB.
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http://www.retrovirology.com/content/11/1/51conserved Valine (V) at position 107 - which was replaced
with Glutamate (E). CycT1-V107E was impaired for bind-
ing to Hexim1, Cdk9 and Brd4, and its binding to HIV
Tat was slightly diminished. It also did not bind to
TAR RNA, or 7SK-snRNA. Consequently, CycT1-V107E
could not support Tat transactivation in murine cells
and efficiently inhibited basal Tat-independent and Tat-
dependent HIV transcription from the HIV LTR promoter
in human cells. Inhibition of HIV transcription by HA-
CycT1-V107E mutant was specific as it did not the inhibit
CMV promoter.
Inspection of the recently published P-TEFb-Tat-TAR
three-dimensional structures illustrates that the Valine at
position 107 does not contact with TAR and is not part
of the TRM (Tat-TAR Recognition Motif ) on CycT1.
CycT1-V107 also does not reside within the Hexim1/Tat-CycT1 binding surface. However, it is located adjacent
to the hydrophobic pocket on CycT1, which is formed by
the two N-terminal helices of the cyclin box and consti-
tutes the binding surface of CycT1 to Tat and Hexim1
[18,29,30,34,35]. Indeed, positioning the V107E mutation
on the 3D structure of the CycT1-Tat fusion protein from
EIAV confirms that it is located on the H4 helix at the first
cyclin box. Residues on helices H4 and H5 and the
Tat-interacting loop define the Hexim1/Tat hydrophobic
binding pocket. Together with TRM at the C-terminal
helix of CycT1-cyclin box, this pocket forms the binding
site for Tat [35]. As such, V107 may well interact with Tat,
as it is in close proximity to I105 and A108 residues that
are part of the Tat-interacting loop. In addition, the last
visible residue (Leu 68) of EIAV-Tat in this model is also
inserted into the defined hydrophobic pocket behind helix
Figure 5 HA-CycT1-V107E mutant enforces repression of HIV transcription. a) J-LTR-Tat-BFP control cells or J-LTR-Tat-BFP cells that stably
express either HA-CycT1-wild type, or HA-CycT1-V107E (J-LTR-Tat-BFP/HA-CycT1-wild type; J-LTR-Tat-BFP/HA-CycT1-V107E) were activated with
TNFα 24 hr. post activation cells were washed and further maintained for additional two weeks. At the indicated time points post activation, cells
were analyzed for their LTR-BFP expression by FACS. b) J-LTR-Tat-BFP cells that stably express HA-CycT1-V107E (J-LTR-Tat-BFP/HA-CycT1-V107E)
were activated with TNFα and cells were maintained for additional growth. At the indicated time points post activation, BFP expression was
monitored by FACS. At day 35-post initial activation, cells were again activated with TNFα. Cells were maintained for additional 25 days (60 days
post initial activation), during which, HIV-LTR-BFP expression was measured by FACS.
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the N-terminus cyclin box repeat of CycT1 (which on
Cdk2 is located on helix H1 and is known to be part of
the recognition motif of the cyclin to its substrate or
inhibitors), also constitutes part of the Tat binding
surface of CycT1 [37,38]. Overall, the change from a
hydrophobic-non-charged Valine residue to a negatively
charged and hydrophilic Glutamate residue may disrupt
the conformation of the Tat/Hexim1 pocket and thus,
explain impaired binding of CycT1 to Hexim1, Tat and
possibly TAR [35]. The crystal structure of the Tat-P-
TEFb complex, containing HIV-1 Tat, Cdk9 and human
CycT1 also demonstrates that Tat adopts a structure
complementary to the surface of P-TEFb and makes
extensive contacts, mainly with the CycT1, but also with
the T-loop of the Cdk9 subunit (Figure 6b). We think that
the fact that CycT1-V107E does not bind Cdk9, also may
explain its reduced binding of CycT1 to Tat [30]. Finally,
the structure of the tripartite complex consisting of the
recognition regions of Cdk9, CycT1 and AFF4 also shows
that AFF4 binds the C-terminal domain of the cyclin box
of CycT1, at the opposite surface of the Cdk9 binding
region and far away from helix H4 that carries V107. This
explains the ability of the V107E CycT1 mutant to
strongly bind AFF4 (Figure 6a) [18]. The recent published
structure of HIV Tat complexed with P-TEFb and AFF4
confirms the above data and clearly shows that upon for-
mation of the Tat-AFF4 and P-TEFb complex, concerted
structural changes in AFF4 occur via a shift of helix H5'of CycT1 and the α-310 helix of AFF4. This structure
shows that the TRM of CycT1 interacts with both Tat and
AFF4, leading to the exposure of arginine side chains
for binding to TAR RNA. Furthermore, modeling of Tat
Lys28 acetylation suggests that the acetyl group would
be in a favorable position for H-bond formation with
Asn257 of TRM, thereby stabilizing the TRM in CycT1,
and provides a structural basis for the modulation of
TAR RNA binding by acetylation of Tat Lys28 [39].
Our analysis demonstrated that other mutants within
the Tat-Hexim1 “binding pocket” were also impaired for
Tat transactivation in murine cells. CycT1-Q56, I59F, the
triple [Q46A;Q50A;F176A], L170W, W221R, C111R and
P249 mutants are all positioned on the opposite helix of
CycT1, around the Y175 residue and according to our
analysis could not support Tat function in murine cells.
CycT1-Y175 is positioned within the groove that is located
between the two cyclin folds of CycT1 and forms an H-
bond with Tat. As such, it defines the surface opposite
of the Tat binding surface. Q46 and Q50 belong to the
Y175 H-bond network and were previously reported to
disrupt Tat binding and transactivation [40]. Importantly,
the Y175-HA-CycT1 mutants, as well as other members
of Group III are the first single-amino-acid mutations to
be reported as impaired for binding of CycT1 to Hexim1
and Tat (Verstraete et.al under revision). HA-CycT1-
Y175S or Y175E were also impaired for rescue of Tat
transactivation in murine cells and binding to RNA
(Verstraete et.al under revision). However, other HA-
Figure 6 Illustration of CycT1-V107E on the 3D structures of P-TEFb. a) The V107E mutation in CycT1 was positioned on the structure of P-
TEFb and AFF4/SEC. It is located on the H4 helix of the cyclin box (pale yellow) and in distance from the AFF4 binding surface and the binding region
of CycT1 to Cdk9 (grey) [18]. b) Cyclin T1 mutations were positioned on the N-terminal helices in the cyclin box of the 3D structure of Tat and P-TEFb
(Cdk9/CycT1) [18,30]. The N-terminal CycT1 cyclin fold is in pale yellow, the C-terminal one is in pale cyan, Tat is in red and Cdk9 is in light grey. This
structure shows that Tat adopts a structure and the T-loop of the Cdk9. Mutations that abolished Tat transactivation in murine cells are also presented.
The V107 residue is indicated in black. c) Model of CycT1-V107E mode of function - CycT1-V107E does not bind Hexim1 and Cdk9, as well as to TAR RNA
and 7SK snRNA. However, its binding to Tat and AFF4 is not impaired. As a result, both Tat and SEC are squelched from the HIV promoter, leading to
repression of both Tat-independent and Tat-dependent HIV transcription. Significantly, CycT1-V107E allows the dissection of binding surfaces that are
involved in either Tat or Hexim1 binding. Moreover, it signifies the importance of SEC for HIV transcription and can serve as a tool to dissect effects of
P-TEFb and SEC on either Tat independent and Tat dependent transcription.
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http://www.retrovirology.com/content/11/1/51CycT1 mutants in Group III, N60K and L133R, did not
bind to Hexim1, but supported (to some extent) Tat
function, despite weak binding to Cdk9. These resultsimply that the Hexim1/Tat binding surface on CycT1 is
not completely overlapping. Overall, our results signify the
important role of the N-terminal helices of CycT1 in the
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in both helices disrupt the pocket and inhibit Tat/Hexim1
and also Cdk9 binding, thus inhibit Tat function.
The current study also shows that most HA-CycT1-N-
terminal mutants bound AFF4/SEC. Thus, N-terminal
helices of CycT1 may not contribute much to the binding
of CycT1 to AFF4/SEC. Those CycT1 N-terminal mutants
that did bind AFF4, also could not associate with Cdk9
or Hexim1 (Group IV). This implies that Cdk9 and/or
Hexim1 plays a role in the association of P-TEFb with
SEC, and assembly of these complexes on the HIV pro-
moter. Indeed structural studies confirm show that the
Hexim1/Tat binding surface on CycT1 does not overlap
with that of AFF4 [18]. Moreover, these studies also
demonstrate that CycT1-N-terminus 300 residues are
mapped for AFF4 binding [18]. Our study significantly
identifies the N-terminal residues of CycT1 that are
involved in AFF4/SEC recruitment versus those that are
contributing to Tat-Hexim1 binding. Importantly, HA-
CycT1 mutants that exhibited impaired binding to AFF4
were part of Group IV that did not associate with Cdk9 or
Hexim1 in cells.
Effects of HA-CycT1-V107E on HIV transcription were
also tested in human Jurkat T cells that stably express
integrated HIV-LTR-Tat BFP (J-LTR-Tat-BFP). These cells
express low levels of BFP, thus serve as model cell lines
for HIV latency. Stable expression of HA-CycT1-V107E
in J-LTR-Tat-BFP cells (J-LTR-Tat-BFP/CycT1-V107E)
inhibited HIV transcription and enforced entrance of
HIV into latency. In contrast, expression of HA-CycT1-
wild-type in these cells led to enhancement of HIV
transcription (Figure 5). As expected, activation of cells
with TNFα led to an overall enhancement of HIV tran-
scription in all cells that expressed either wild type or
V107E HA-CycT1. However, while expression of CycT1-
V107E accelerated transcription silencing of HIV in a
12-day post activation time-frame, HIV transcription in
cells that expressed wild type-HA-CycT1 remained
activated and finally went through apoptosis (Figure 5).
Similarly, HIV transcription in J-LTR-Tat-BFP control
cells that did not express HA-CycT1 gradually decreased,
but still remained high in the 12-day time frame post
activation (Figure 5). We conclude that CycT1-V107E
accelerates silencing of HIV transcription and enforces
latency. Repression of HIV transcription in J-LTR-Tat/
HA-CycT1-V107E cells was also detected in longer
time points. A second activation of J-LTR-Tat-BFP/HA-
CycT1-V107E cells, resulted in full restoration of HIV
transcription. However, as for the first cycle of TNFα
activation, HA-CycT1-V107E expressing cells quickly
reverted back to a resting state and remained as such up
to 60 days post initial activation with TNFα (Figure 5).
Inhibitory effects of CycT1-V107E mutant were also
tested in human CD4(+) primary cells. In these cells, stableexpression of CycT1-V107E mutant also repressed HIV
replication - up to 60% (Figure 4b). Current experiments
are attempting to improve gene marking of CD4(+) primary
cells and elevate the repressive effects on transcription of
CycT1-V107E (Figure 4b).
This study aims to understand the mode of function of
CycT1-V107E. We hypothesize that strong binding of
CycT1-V107E to AFF4/SEC and slightly weaker binding
to Tat, but not to RNA, Hexim1 and Cdk9, may squelch
SEC and Tat from the viral promoter, prompting efficient
silencing of HIV transcription in human cells (Figure 6c).
These results signify the role of SEC, P-TEFb and Tat in
regulating HIV transcription and the importance of
SEC and Tat in promoting HIV latency. The inability of
HA-CycT1-V107E mutant to assemble on Hexim1 and
7SK snRNA may also shift the equilibrium of P-TEFb
towards its inactive complex, enhancing the inhibition
of P-TEFb activity and repression of transcription from
the HIV promoter.
Binding experiments of HA-CycT1 to Hexim1, Cdk9
Tat, TAR and 7SK snRNA, identified other mutants that
belong to the same group of CycT1-V107E (Group IV).
These mutants did not bind Cdk9 and Hexim1 and did
not support Tat transactivation in murine cells. These
include HA-CycT1-L203P, U7 and the quadruple mutant
T143A;T149A;T155A;E137D. Interestingly, HA-CycT1-
V107E was the only mutant in this group that effectively
bound to AFF4 subunit of SEC and yet exhibited domin-
ant negative inhibition phenotype on HIV transcription
in human cells. These results suggest that in the syner-
gistic transcriptional effects of P-TEFb and SEC on the
activity of RNA polymerase, the recruitment of SEC to
the HIV promoter is highly significant for enhancing
viral transcription.
Overall, this work defines the binding surfaces of CycT1
to Hexim1 which may be spreadable from those of Tat. It
also describes for the first time a V107E-CycT1 mutation
that effectively inhibits Tat independent and Tat dependent
transcription from the HIV promoter. As CycT1-V107E
does not bind Cdk9 and TAR, but strongly binds to AFF4
and its association with Tat is slightly impaired, it can serve
as a unique tool to dissect the effects of SEC on HIV
transcription.
Conclusions
This work defines N-terminus binding residues of CycT1
to Cdk9, AFF4, RNA and Hexim1. Binding of Hexim1 to
CycT1 could be dissected from that of Tat. Significantly,
our analysis also describes for the first time a unique
V107E-CycT1 mutation that effectively suppresses Tat
independent and Tat dependent transcription from the
HIV promoter in both human T cell lines and in CD4(+)
primary T cells. CycT1-V107E does not bind Hexim1,
Brd4, and Cdk9, and does not assemble on TAR RNA,
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associates with Tat. As such, it serves as a unique tool
for studying the effects of SEC on HIV transcription
that are P-TEFb independent, and signifies the import-




HA-CycT1 mutants were generated in the context of
the CycT1-(1–280) residues, and cloned in a pHAGE-
CMV-IRES-puromycin lentiviral vector (a generous gift
of the Mulligan lab - HMS). The HA-tag was positioned
at the C-terminus of the protein. Stable cells expressing
CycT1-V107E were generated following transduction,
by puromycin selection. pCDNA3-myc-Tat and HIV-
LTR-Luciferase were used for transient transfection and
analysis of CycT1 effects in murine cells. pRL-Renila was
used in these assays for control of transfection efficiencies
(Promega). In human cells, LTR-Tat-BFP reporter provirus
was used (based on the pHRP-PNL-d2EGFP a generous
gift of J. Karn; the BFP protein replaced the deEGFP)
[36]. pCDNA3-CMV-GFP expression plasmid was used
for transfection efficiencies in these assays. For protein
and RNA binding experiments between HA-CycT1 and
P-TEFb partners, HEK293T cells were co-transfected
with the pHAGE-CMV-HA-CycT1 lentiviral vector and
pCDNA3-Flag-Tat. For infection of Jurkat cells and
human primary CD4(+) cells, VSV-G pseudotyped len-
tivirus expressing a Blue Florescence Protein (BFP)
reporter under the control of the HIV promoter was
used (HIV-LTR-BFP).
Cells
HEK-293T human cells; 3T3 murine cells and Jurkat T
cells were respectively maintained in complete 10% FCS
DMEM or RPMI-1640, at 37°C with 5% CO2.
Cyclin T1 mutants
A collection of CycT1 mutants cloned in yeast hybrid
vector were generated by Verstraete et. al. (submitted).
Mutant CycT1-cyclin box domain (1–280 residues) were
amplified by 30 cycles of PCR. The reverse 3’ primer also
contained HA-tag sequence for the expression of a C-
terminus HA tag. PCR fragments were digested with
BamHI/NotI and inserted into the same sites in pHAGE
lentiviral vector.
Production of HIV lentiviruses
VSV-G pseudotyped single round particles were produced
by CaPO4 co-transfection into HEK-293T of the lentiviral
transvector (either the proviral LTR-Tat-BFP, or HA-CycT1
mutants) plasmid, HIV gag/pol, pRev, pTat and the VSV-G
envelope. 48 hr. post transfection, cell supernatant washarvested, centrifuged and filtered through 0.45 μ filter.
Lentiviruses were concentrated by ultracentrifugation for
2 hr. at 25 K rpm, and the pellet was suspended in PBS.
Aliquots of viral stocks were frozen. Titer of viruses was
determined by transduction of HeLa cells with viral serial
dilutions. 48 hr. post transduction, cells were harvested
and analyzed by FACS for BFP expression.Binding of CycT1 mutants in cells
HEK-293T cells grown in 10 cm plate were transfected
with 10 μg of the indicated pHAGE-HA-CycT1 plasmid,
using Lipofectamine 2000 (Invitrogen). Cells were also
transfected with 5 μg of LTR-Luc, 5 μg FLAG-Tat and
2 μg of pCDNA-CMV-GFP to measure transfection effi-
ciencies (48 hr. post transfection, 90% of cells were
green). 48 hr. post transfection, cells were lysed with an
hypotonic buffer (0.1% Triton; 20 mM Tris-Cl pH 7.6;
200 mM NaCl; 0.72 mM EDTA; 10% Glycerol; 14 mM
β-Mercaptoethanol (added fresh before use, 1:1000); pro-
tease inhibitors (PI; Sigma; 1/200 dilution). Lysates were
incubated on ice for 1 hr. and then and centrifuged at
14,000 rpm for 10 min at 4°C. Cleared supernatants were
then incubated overnight with gentle rocking with 1 μg of
α-HA antibody (Abcam ab-9110). Following, lysates were
incubated with BSA-pre-blocked protein A-sepharose
beads (Invitrogen) at 4°C for 2 hr. with gentle rocking.
Beads were extensively washed ×4 times with washing
buffer (lysis buffer containing 0.05% Triton), and were
then precipitated by centrifugation at 3000 rpm at 4°C.
Immuno-Precipitated (IP) proteins were separated on
SDS-PAGE and analyzed by western blotting (WB)
with the indicated antibodies diluted in PBS; α-Hexim1
(ab25388); α-Cdk9 (ab6544); α-AFF4 (ab 57077,); α-Flag
(M2-Sigma); α-Brd4 (ab75898); Secondary antibodies were
α-mouse (Jackson-115035062) and α-rabbit (Jackson-
111035045).Analysis of Tat transactivation in murine and human cells
To measure the ability of HA-CycT1 mutants to support
HIV Tat transactivation in murine cells, the following
DNA plasmids were transiently co-transfected into 3T3
cells, using Lipofectamine 2000 (Invitrogen). LTR-Luc
(0.1 μg); pCDNA-myc-Tat (0.2 μg); pHAGE-HA-CycT1
mutant, or pHAGE-HA-CycT1 wild type (2 μg). 6 hr. post
transfection, media was replaced with fresh complete
DMEM. Cells were harvested 48 hr. post transfection and
lysed with 100 μl of luciferase lysis buffer (Promega). 20 μl
of sample was used for luciferase measurements according
to the manufacturer instructions. Activation of HIV-Tat
activity upon expression of human CycT1 was used as
control - set to 100. All luciferase activities were measured
relatively to the wild type CycT1. Transfection efficiencies
were normalized between wells by monitoring Renila
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ase Reporter Vector (200 ng/24 well).
In human cells
Tat-independent inhibitory effects of HA-CycT1 mutants
were monitored by transiently co-transfecting pHAGE-
HA-CycT1 mutant (2 μg) and the HIV-LTR-luciferase
reporter (0.1 μg). pRL Renilla Luciferase Reporter Vector
(Promega) (200 ng/24well) was used to measure transfec-
tion efficiencies and luciferase readings were normalized
to the Renilla expression.
For analysis of inhibition of Tat-dependent transactivation
pHAGE-HA-CycT1 mutants were transfected (2-4 μg) with
the LTR-Tat-BFP lentiviral vector (1 μg). pCDNA3-CMV-
GFP (0.1 μg) was also transfected into cells, to monitor
transfection efficiencies 48 hr. post transfection, cells were
harvested and their BFP expression were measured by
FACS relatively to cells that expressed wild type HA-
CycT1. Data were presented as (−) or (+) representing in-
hibitory affects on HIV transcription in human cells.
For effects of HA-CycT1 mutants on the NF-kB or
CMV promoters, HA-CycT1 mutants were transfected
with into human HEK-293T cells (2-4 μg) together with
either the NF-kB-Luciferase promoter or the CMV-BFP
promoter (1 μg). Cells were harvested 48 hr. post trans-
fection and analyzed for their luciferase activity or BFP
expression by FACS. Data are presented relatively to ef-
fects of CycT1-wild type –set to 100.
Generation of Jurkat T cell line models for HIV latency
that express HA-CycT1 and analysis of effects on HIV
transcription
Jurkat (J)-LTR-Tat-BFP cells were generated following
transduction of VSV-G pseudotyped HIV-LTR-Tat-Rev-
BFP lentivirus. In these lentiviruses, Tat and Rev are
expressed in cis under the control of the HIV LTR
promoter, as described by the Karn lab [36]. The BFP
reporter gene replaced the 2dEGFP gene which was
inserted downstream of the Tat-Rev genes. Transduced
cells were maintained for growth for a long period of
time (up to a month), allowing the integrated HIV pro-
virus to enter transcription silencing. In these cells, basal
HIV transcription reached to 10%, and upon activation
with TNFα, 100% of cells expressed BFP - implying tran-
scription silencing of the integrated Tat-BFP provirus. For
stable expression of HA-CycT1 in J-LTR-Tat-BFP, cells
were transduced with pseudotyped lentiviruses expressing
CycT1 (wild type or V107E) and 48 hr. post transduction,
cells were selected on puromycin for a week. HA-CycT1
expression was validated by Western blot and effects on
HIV transcription were monitored by FACS, measuring
expression of BFP.
To analyze effects of HA-CycT1-V107E on HIV tran-
scription following TNFα activation and over longer timeframes, J-LTR-Tat-BFP/CycT1-wild type, or CycT1-V107E
mutant were activated with 10 μg/ml TNFα for 24 hr. BFP
expression was monitored by FACS at the indicated time
points. For longer-time points, cells were again activated
again by TNFα for 24 hr. at 30 days post initial activation
and cells were further analyzed for their BFP expression
for additional 30 days (60 days post initial activation).
Transduction of CD4+ primary T cells and infection with HIV
Human CD4+ cells were isolated from naïve PBMCs
using CD4+ T cells isolation kit (RosetteSep), followed
by centrifugation via density gradient medium. CD4+ T
cells were stimulated with CD3/CD28 beads for 48 hr.
and then transduced with HA-CycT1-V107E or HA-CycT1
wild type expressing lentivirus. 48 hr. post transduction,
cells were infected with HIV-LTR-Tat-BFP lentivirus at
an MOI of 1. As control cells were also transduced with
a CMV-BFP infectious lentivirus. Viral replication was
measured by FACS.
RNA Precipitation
HEK-293T cells were grown on 10 cm plates and were
co-transfected with 10 μg of pHAGE-HA-CycT1 mutants
(or HA-CycT1-wild type), 5 μg of HIV LTR-Luc, 5 μg
pCDNA-CMV-Myc-Tat and 2 μg of pCDNA-CMV-GFP.
48 hr. post transfection, 90% of cells expressed GFP,
indicating high transfection efficiency. Cells were lysed
with 800 μl of RNA-IP buffer, supplemented with RNAse
inhibitors (NEB) and protease inhibitors (Lysis buffer
containing; 0.5% NP-40; 20 mM HEPES pH 7.8; 100 mM
KCl; 0.2 mM EDTA; PI cocktail Sigma (add fresh before
use, 1:100); RNAse inhibitor (NEB). Cell lysates were
incubated on ice for 10 min. and centrifuged at 5000Xg
for 5 min at 4°C. Supernatants were collected and then
divided into two aliquots. The first was incubated over-
night with gentle rocking with 1 μg of anti-HA antibody
(ab-9110), and the second was incubated with control
non-immune anti-human IgG. Next, protein A-Sepharose
beads were pre-blocked with BSA and yeast tRNA and
then were added for additional 2 hr. at 4°C. 50 μl of cell
lysate was collected for input and stored at −80°C till RNA
extraction. Beads were then extensively washed with
washing buffer containing; 0.1% NP-40; 20 mM HEPES
pH 7.8; 100 mM KCl; 0.2 mM EDTA; PI cocktail Sigma
(add fresh before use, 1:100); RNAse inhibitor (NEB).
Washing was performed for 10 min with gentle rocking at
4°C, while eppendorf tubes were replaced at least once to
avoid unspecific RNA binding to the tubes. Following
wash, beads were centrifuged 3000 rpm for 3 min. Beads
were re-suspended in 100 μl of lysis buffer and extracted
with 100 μl Tris-Phenol and chloroform followed by etha-
nol precipitation. Input samples were extracted using the
same protocol. RNA concentrations were measured and
1 μg was used for the synthesis of cDNA, using cDNA
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20 μl. Inputs were re-suspended in 20 μl of DEPC water
as well. IP RNA was then subjected to cDNA synthesis,
which was further analyzed by real-time PCR analysis
using KAPA SYBER GREEN fast mix with TAR and 7SK
snRNA specific primers. 2 μl of 1:10 and 1:100 dilution of
input were used to generate a standard curve and deter-
mine the quality control of the reaction. 2 μl of undiluted
IP samples were used as templates. Reactions were ana-
lyzed in triplicates and presented as fold of enrichment
relatively to PCR results obtained for cells transfected with
LTR-Luc alone - set to 1.
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